Clinical Trials in San Antonio

Showing 3141-3160 of 12,572 trials

A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

NCT06917508

The primary aim of this study is to assess the effect of EDP-323 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy adult participants.

RSV InfectionDrug Drug Interaction

Enanta Pharmaceuticals, Inc24 participantsStarted Mar 2025

San Antonio, Texas, United States

RECRUITINGPhase 1< 1 mile

SGLTi, Hepatic Glucose Production and Ketogenesis

NCT05960656

In this study, we will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) and type 1 diabetes (T1D), and that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. We will conduct five distinct experiments to test this hypothesis in patients with T2D and T1D. MAIN STUDY: To examine the effect of empagliflozin versus empagliflozin/pancreatic clamp on EGP (6,6, D2-glucose), gluconeogenesis (D2O), lipolysis (U-2H-glycerol), ketogenesis (13C-palmitate conversion to 3-betahydroxybuyrate), and norepinephrine turnover (3H-NE) in type 2 diabetes subjects.

Type 2 Diabetes

The University of Texas Health Science Center at San Antonio30 participantsStarted Oct 2023

San Antonio, Texas, United States

RECRUITINGPhase 3< 1 mile

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451

The purpose of this trial is: 1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines 2. to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment 3. to collect safety data in this population for up to three years after the last dose of study treatment

Chronic Spontaneous Urticaria

Novartis Pharmaceuticals100 participantsStarted Jul 2023

Bakersfield, California, United States • San Diego, California, United States • Coral Gables, Florida, United States +60 more locations

A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

SGLTi, Hepatic Glucose Production and Ketogenesis

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Find Trials by Condition in San Antonio

Use of Aromatherapy in Conjunction With Physical/Occupational Therapy in an Acute Care Setting

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

Vaginal Ecosystem and Network in the United States Study

Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Distal Radius Interventions for Fracture Treatment

Adolescent Master Protocol

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

Cough Reduction in IPF With Nalbuphine ER